<SEC-DOCUMENT>0001104659-19-069262.txt : 20191203
<SEC-HEADER>0001104659-19-069262.hdr.sgml : 20191203
<ACCEPTANCE-DATETIME>20191203094217
ACCESSION NUMBER:		0001104659-19-069262
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20191201
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191203
DATE AS OF CHANGE:		20191203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOANALYTICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23357
		FILM NUMBER:		191264763

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETT
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm1924272d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
December 1, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">BIOANALYTICAL SYSTEMS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Exact name of registrant as specified in its charter)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Indiana</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">0-23357 </FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">35-1345024</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation or organization)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2701 KENT AVENUE</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WEST LAFAYETTE, INDIANA</P></TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 48%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">47906-1382</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Registrant's telephone number, including
area code: (765) 463-4527</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act(17CFR240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act(17CFR240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act(17CFR240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt"><FONT STYLE="font-size: 10pt">Securities registered pursuant to Section 12(b) of the Act:</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 37%; border-left: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 28%; border-left: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Ticker symbol(s)</FONT></TD>
    <TD STYLE="width: 35%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Common Shares</FONT></TD>
    <TD STYLE="border-left: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">BASi</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">NASDAQ Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><B><BR STYLE="clear: both">&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><B>Item 1.01 Entry into a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information set
forth in Item 2.01 regarding the Credit Agreement Amendment (as defined below) is incorporated by reference into this Item 1.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.01 Completion of Acquisition
or Disposition of Assets.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As previously disclosed,
on November 8, 2019, Bioanalytical Systems, Inc. (the &ldquo;<U>Company</U>&rdquo;), and Bronco Research Services LLC, a wholly
owned subsidiary of the Company (the &ldquo;<U>Purchaser</U>&rdquo;), entered into an Asset Purchase Agreement (the &ldquo;<U>Purchase
Agreement</U>&rdquo;) with Pre-Clinical Research Services, Inc., a Colorado corporation (the &ldquo;<U>Seller</U>&rdquo;), and
its shareholder (the &ldquo;<U>Shareholder</U>&rdquo;). On December 1, 2019, the Company closed the transactions contemplated by
the Purchase Agreement, indirectly acquiring (the &ldquo;<U>Acquisition</U>&rdquo;) substantially all of the assets of Seller used
or useful by Seller in connection with Seller's provision of good laboratory practice (&quot;<U>GLP</U>&quot;) and non-GLP preclinical
testing for the pharmaceutical and medical device industries. The consideration for the Acquisition consisted of $1,500,000 in
cash, subject to certain adjustments, 240,000 of the Company&rsquo;s common shares and an unsecured promissory note in the initial
principal amount of $800,000 made by Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the
previously announced terms of the Acquisition, Purchaser also purchased from an affiliate of Shareholder certain real property
located in Fort Collins, Colorado, comprising the main facility for the Seller&rsquo;s business and additional property located
next to the facility available for future expansion, for $2,500,000. As contemplated by the Purchase Agreement, the Purchaser also
entered into a lease arrangement for an ancillary property used by Seller&rsquo;s business, located in Livermore, Colorado.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to finance
the Acquisition and the real property purchase, as well as provide additional capital to fund growth efforts, the Company amended
and restated its credit arrangements with First Internet Bank (the &ldquo;<U>Credit Agreement Amendment</U>&rdquo;) to, among other
things, (i) increase the principal amount of the Company&rsquo;s amended and restated revolving note from $3,500,000 to $5,000,000
with a maturity of January 31, 2021 and interest payments only until maturity at a floating per annum rate equal to the greater
of (a) four percent (4%), or (b) the sum of the Prime Rate plus Zero Basis Points (0.0%), which rate shall change concurrently
with the Prime Rate, (ii) add a capital expenditure line of credit in the principal amount of $3,000,000 with a maturity of December
31, 2020 and interest payments only until maturity at a floating per annum rate equal to the greater of (a) four percent (4%),
or (b) the sum of the Prime Rate plus Fifty Basis Points (0.5%), which rate shall change concurrently with the Prime Rate, (iii)
add a new term loan in the principal amount of $1,500,000 with a maturity of June 1, 2025, interest at a fixed per annum rate equal
to four percent (4%) and with interest payments only commencing January 1, 2020 through June 1, 2020, with monthly payments of
principal and interest thereafter through maturity and (iv) add an additional new term loan in the principal amount of $1,939,000
with a maturity of December 1, 2024 and interest at a fixed per annum rate equal to four percent (4%), with payments of principal
and interest due monthly through maturity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the Credit
Agreement Amendment, the Company&rsquo;s obligations under the Amended and Restated Credit Agreement are guaranteed by BAS Evansville, Inc. (&ldquo;<U>BASEV</U>&rdquo;), Seventh Wave Laboratories, LLC (&ldquo;<U>Seventh
Wave</U>&rdquo;), BASi Gaithersburg LLC (&ldquo;<U>BG</U>&rdquo;), as well as the Purchaser (collectively, the &quot;<U>Guarantors</U>&quot;),
each a wholly owned subsidiary of the Company. The Company&rsquo;s obligations under the Credit Agreement and the Guarantor's obligations
under their respective guaranties are secured by first priority security interests in substantially all of the assets of the Company
the Guarantors, respectively, as well as mortgages on the Company&rsquo;s, BASEV&rsquo;s and the Purchaser&rsquo;s facilities in
West Lafayette, Indiana, Evansville, Indiana, and Fort Collins, Colorado, respectively, and pledges of the Company&rsquo;s ownership
interests in its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Amended and Restated
Credit Agreement includes financial covenants consisting of (i) a Fixed Charge Coverage Ratio (as defined in the Amended and Restated
Credit Agreement) of not less than 1.25 to 1.0, tested quarterly and measured on a trailing twelve (12) month basis and (ii) beginning
March 31, 2020 a Cash Flow Leverage Ratio (as defined in the Amended and Restated Credit Agreement), tested quarterly, as follows:
not to exceed (a) as of March 31, 2020, 5.00 to 1.00, (b) as of June 30, 2020, 4.50 to 1.00, (c) as of September 30, 2020, 4.25
to 1.00 and (d) as of December 31, 2020 and each quarter thereafter, 4.00 to 1.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing description
of the Credit Agreement Amendment does not purport to be complete and is qualified in its entirety by the terms and conditions
of the Company&rsquo;s Amended and Restated Credit Agreement, a copy of which will be filed as an exhibit to the Company&rsquo;s
Quarterly Report on Form 10-Q for the quarterly period ending December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2.03 Creation of a Direct Financial Obligation or an
Obligation under an Off-Balance Sheet Arrangement of a Registrant.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information set forth in Item 2.01 regarding
the Credit Agreement Amendment is incorporated by reference into this Item 2.03.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 3.02 Unregistered Sales of Equity Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Purchase
Agreement, the Company issued 240,000 of the Company&rsquo;s common shares to the Seller. The shares were issued in reliance upon
the exemption from the registration requirements of the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;),
provided by Section 4(a)(2) of the Securities Act as sales by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7.01 Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 3, 2019,
the Company issued a press release announcing the completion of the Acquisition, a copy of which is attached to this Current Report
on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed &ldquo;filed&rdquo; for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), or incorporated
by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference
in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) Financial Statements of Business Acquired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company intends to file the financial
statements of Seller required by Item 9.01(a) as part of an amendment to this Current Report on Form 8-K not later than 71 calendar
days after the date that this Current Report on Form 8-K is required to be filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) Pro Forma Financial Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company intends to file the pro forma
financial information required by Item 9.01(b) as part of an amendment to this Current Report on Form 8-K not later than 71 calendar
days after the date that this Current Report on Form 8-K is required to be filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><A HREF="tm1924272d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD><TD STYLE="text-align: justify"><A HREF="tm1924272d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press Release dated December
3, 2019</FONT></A></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Bioanalytical Systems, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: December 3, 2019</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Robert Leasure, Jr.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Robert Leasure, Jr.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm1924272d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;<IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; color: #6C717A"><B>NEWS RELEASE</B></P>



<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: right"><B>FOR MORE INFORMATION:</B></TD>
    <TD STYLE="width: 40%; text-align: right"><B>Company Contact:</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">Jill C. Blumhoff</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">Phone: 765.497.8381</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">jblumhoff@inotivco.com</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; color: #6C717A"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Inotiv, a BASi Company, Announces Closing
of Pre-Clinical Research Services Transaction, Including New Financing to Fund the Transaction and Expand Discovery and DMPK Business&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WEST LAFAYETTE, Ind., December 3, 2019
--&nbsp;Bioanalytical Systems, Inc.&nbsp;(NASDAQ:BASI) (&ldquo;BASi&rdquo; or the &ldquo;Company&rdquo;) doing business as Inotiv,
a leading provider of nonclinical and analytical contract research services, announced today the closing of the <U>previously
announced agreement</U> to purchase substantially all of the assets of Pre-Clinical Research Services, Inc. (&ldquo;PCRS&rdquo;),
a premier provider of surgical and medical device contract research services. <FONT STYLE="color: #212121; background-color: white">In
connection with the closing, the Company also closed on additional funding, which positions the Company to make future investments
in organic growth in the drug metabolism and pharmacokinetics arena.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, which recently announced
the rebranding of the Company&rsquo;s contract research services business under the name <U>Inotiv</U>, closed on the PCRS business
on December 1, 2019. In addition to the previously announced terms of the transaction, the Company purchased real property comprising
the main facility, and additional property located next to the facility which can be available for future expansion, for the PCRS
business for $2,500,000. In order to finance the transaction, as well as provide additional capital to fund growth efforts, the
Company amended and restated its credit arrangements with First Internet Bank to, among other things, increase a current line
of credit under the facility from $3.5 million to $5 million, to add a capital expenditure line of credit in the principal amount
of $3 million, and to add two new term loans in the amounts of approximately $1.5 million and $1.9 million, respectively, the
proceeds of which were used to fund a portion of the purchase price for the PCRS business and acquired real property. A Current
Report on Form 8-K containing further details regarding the transaction and financing will be filed with the U.S. Securities &amp;
Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;I am pleased to announce the completion
of our strategic agreement with PCRS and the new funding for our DMPK business, as we wrap up an exciting year of growth and evolution
as a Company,&rdquo; said Robert Leasure, Jr., the Company&rsquo;s President and Chief Executive Officer. &ldquo;Becoming one with
PCRS allows us to provide broader services by further expanding our toxicology business and allowing us to offer surgical services
for pharmaceutical and medical device clients. We&rsquo;re looking to the new year with optimism, as we continue to focus on providing
our clients with the broad scope and right-sized solutions essential to their success, and an experience of high-touch care and
collaboration.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="footer.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Donald Maul, founder and president
of PCRS, added, &ldquo;We are very optimistic about the positive impact of joining Inotiv. This allows us the opportunity to provide
more complete services to our clients, it creates opportunities for growth for our staff, and it provides a broader, more stable
platform from which to operate. Since announcing the agreement a few weeks ago, feedback from our clients has been overwhelmingly
positive, which serves to validate our strategy.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With this closing, the Company&rsquo;s clients will have the
ability to work with one provider having expertise in a broad range of scientific disciplines, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Pharmacology</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Toxicology</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Drug Metabolism</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Pharmacokinetics</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Bioanalysis</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Intravascular Device and Structural Heart Models</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Surgical and Medical Devices</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Scientific and Regulatory Consulting</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Inotiv, A Bioanalytical Systems, Inc., Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inotiv, a BASi Company, is a pharmaceutical
development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the
world's leading drug development companies and medical research organizations. The Company focuses on developing innovative services
supporting its clients&rsquo; discovery and development objectives for improved decision-making and accelerated goal attainment.
BASi&rsquo;s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit
<U>inotivco.com</U>&nbsp; for more information about Inotiv, A BASi Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release may contain forward-looking
statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes
in the market and demand for our products and services, the development, marketing and sales of products and services, changes
in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business
and financial impact thereof, and various market and operating risks, including those detailed in the Company's filings with the
U.S. Securities and Exchange Commission.</I></P>



<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="footer.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% (H# 2(  A$! Q$!_\0
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MV<@_3UJ7))<S=D-1;=D3T4R*6.>)98G#HPR&!X-/IIIJZ$U;1A1113 ****
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HIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 footer.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  F RX# 2(  A$! Q$!_\0
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M*K2Y/06BD+J!DL,>N:-P..1STK8R%HHSSBDR/4=<4 +1110 449%% !1110
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M>M "T444 ,>6./&^15S_ 'CBF_:8/^>\?_?8K%N%AWZC<3JC.DB*K2)OP..
M/QJ"+RUD!FL"\?=5L""?QS7#+%R4K67X]VOT.R.&35[O\.USH?M,'_/>/_OL
M4]75QE&##U!S7-R- N]A8[$SD%[$_*/<YJ_9+'#K3) JI$]HLA51@$[CSBJI
MXJ4I)-+\?/OZ$SPZC&^OX>7^9KT49&<45V'*%%% (/2@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **SO[5
M;_H'7_\ WZ'^-']JM_T#K_\ []#_ !K'V]/O^#_R-?8S[?E_F:-%9W]JM_T#
MK_\ []#_ !H_M5O^@=?_ /?H?XT>WI]_P?\ D'L9]OR_S-&BL[^U6_Z!U_\
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M_P '_D'L9]OR_P S1HK._M5O^@=?_P#?H?XT?VJW_0.O_P#OT/\ &CV]/O\
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M<'#$C'# <@>I/!K5_M9_^@9?_P#?L?XT?VL__0,O_P#OV/\ &CV]/O\ @_\
M(/8U.WXK_,AT:]G,2PWKR--([F+?&58H .3D#N>N!6=<6%S<7+H@FA)U-I%E
M"GY?W(PWTW#^E:_]JMG/]F7V?7RA_C1_:S_] R__ ._8_P :/;T^_P"#_P @
M]C4[?BO\ROHHO5MM1DEMQ'<O<,RHQ(4ML4<'^[D=:RX+.[A?4S?::ET[K$R@
MYD627D C(''//]T"MS^UG_Z!E_\ ]^Q_C1_:S_\ 0,O_ /OV/\:/;T^_X/\
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M *!U_P#]^A_C1_:K?] Z_P#^_0_QH]O3[_@_\@]C/M^7^9HT5G?VJW_0.O\
M_OT/\:/[5;_H'7__ 'Z'^-'MZ??\'_D'L9]OR_S-&BL[^U6_Z!U__P!^A_C1
M_:K?] Z__P"_0_QH]O3[_@_\@]C/M^7^9HT445L9!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
